武田制药Zasocitinib在头对头3期银屑病研究中表现出显著优势,有望重新定义口服治疗预期

美通社
Jun 12

每日一次口服Zasocitinib在斑块状银屑病研究的所有主要终点和关键次要终点上均较氘可来昔替尼显示出统计学优效性 在第16周,超过35%接受Zasocitinib治疗的患者达到皮损完全清除(PASI 100)——应答率为氘可来昔替尼的2.5倍以上 安全性特征与既往研究一致,未发现新的安全性信号 日本大阪和美国马萨诸塞州剑桥2026年6月12日 /美通社/ -- 武田制药(TSE:4502/...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10